{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:16:18Z","timestamp":1781187378999,"version":"3.54.1"},"reference-count":29,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"1","license":[{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">Promising efficacy and manageable toxicity of docetaxel\u2010based concurrent chemoradiotherapy (CCRT) were reported in head and neck cancer. In addition, the effect of CCRT in combination with cisplatin and\/or 5\u2010fluorouracil on both locoregionally advanced and metastatic\/recurrent nasopharyngeal carcinoma (NPC) was verified. However, CCRT with docetaxel for locoregionally advanced NPC are not well studied. This study aimed to compare effectiveness and toxicities of CCRT with weekly docetaxel versus tri\u2010weekly cisplatin for locoregionally advanced NPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Clinical data of patients with locoregionally advanced NPC newly diagnosed between January 2010 and December 2014 receiving CCRT with either weekly docetaxel (15 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) or tri\u2010weekly cisplatin (80\u2013100 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) were reviewed. Propensity score matching at a 1:1 ratio was performed to balance baseline characteristics. Adverse events and survival were compared between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      A total of 962 patients were included as the whole cohort, and 448 patients were matched and were regarded as the matched cohort. The median follow\u2010up duration was 48 months for the whole cohort. The 3\u2010year nodal recurrence\u2010free survival rate was significantly increased for patients treated with docetaxel in both the whole (hazard ratio [HR] = 0.37, 95% confidence interval [CI] 0.19\u20130.72,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.030) and matched cohorts (HR = 0.33, 95% CI 0.14\u20130.79,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.023). However, no significant differences were observed in overall survival, local recurrence\u2010free survival, and distant metastasis\u2010free survival between the two groups in both cohorts. Significantly higher rates of grade 3 radiodermatitis (6.7% vs. 1.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001), mucositis (74.5% vs. 37.9%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and leucopenia (2.2% vs. 11.6%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) were observed in the docetaxel group, but any grade of renal injury (1.8% vs. 15.1%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), vomiting (18.8% vs. 88.3%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and ALT elevation (19.2% vs. 31.3%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.027) were more common in the cisplatin group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">CCRT with weekly low\u2010dose docetaxel is an effective and tolerable therapeutic regimen for locally advanced NPC. It provides a survival benefit mainly by improving the control of regional lymph node metastases, especially for patients with low pretreatment EBV DNA levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40880-019-0380-x","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T10:02:57Z","timestamp":1561629777000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score\u2010matched analysis"],"prefix":"10.34133","volume":"39","author":[{"given":"Jun\u2010Fang","family":"Liao","sequence":"first","affiliation":[{"name":"National Cancer Center\/Cancer Hospital & Shenzhen Hospital","place":["Shenzhen, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Sun Yat\u2010sen University","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao\u2010Jing","family":"Du","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]},{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Lan","sequence":"additional","affiliation":[{"name":"Cancer Hospital Affiliated to School of Medicine","place":["Chengdu, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Liu","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]},{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun\u2010Fei","family":"Xia","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]},{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu\u2010Yu","family":"Cai","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]},{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Luo","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]},{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2019,6,27]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40880\u2010017\u20100257\u20109"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2011.02.012"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr432"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(15)70126\u20109"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1310"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031317"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.5633"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30410\u20107"},{"key":"e_1_3_2_11_2","first-page":"1842","article-title":"Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells","volume":"56","author":"Hennequin C","year":"1996","unstructured":"Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res. 1996; 56: 1842\u20131850.","journal-title":"Cancer Res."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3727\/0965040041791455"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23321"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi018"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147\u2010003\u20100375\u2010z"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2014.06.014"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1545"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2005.01.008"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40880\u2010018\u20100283\u20102"},{"issue":"6","key":"e_1_3_2_20_2","first-page":"1188","article-title":"Quantitative analysis of cell\u2010free Epstein\u2010Barr virus DNA in plasma of patients with nasopharyngeal carcinoma","volume":"59","author":"Lo YM","year":"1999","unstructured":"Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, et al. Quantitative analysis of cell\u2010free Epstein\u2010Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999; 59 (6): 1188\u20131191.","journal-title":"Cancer Res."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20099"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002642"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.009.10435"},{"key":"e_1_3_2_24_2","unstructured":"National Comprehensive Cancer Network for Head and Neck Cancers . Version 1. 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head\u2010and\u2010neck. Accessed 1 Sept 2018."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2012.13.3.785"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360\u20103016(95)00216\u2010L"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyg054"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360\u20103016(03)01370\u20101"},{"issue":"9","key":"e_1_3_2_29_2","first-page":"4013","article-title":"Hyperfractionated radiotherapy with concurrent docetaxel for advanced head and neck cancer: a phase II study","volume":"32","author":"Karasawa K","year":"2012","unstructured":"Karasawa K, Matsumoto F, Ito S, Oba S, Furuya T, Hirowatari H, et al. Hyperfractionated radiotherapy with concurrent docetaxel for advanced head and neck cancer: a phase II study. Anticancer Res. 2012; 32 (9): 4013\u20134018.","journal-title":"Anticancer Res."},{"issue":"3","key":"e_1_3_2_30_2","first-page":"XC01","article-title":"Feasibility and response of concurrent weekly docetaxel with radical radiotherapy in locally advanced head and neck squamous cell carcinoma","volume":"9","author":"Jomon Raphael C","year":"2015","unstructured":"Jomon Raphael C, Rajesh I, Rajesh B, Selvamani B, John S. Feasibility and response of concurrent weekly docetaxel with radical radiotherapy in locally advanced head and neck squamous cell carcinoma. J Clin Diagn Res. 2015; 9 (3): XC01\u2013XC04.","journal-title":"J Clin Diagn Res."}],"updated-by":[{"DOI":"10.1186\/s40880-019-0396-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:00:00Z","timestamp":1569196800000}}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-019-0380-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40880-019-0380-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1186%2Fs40880-019-0380-x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-019-0380-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1186\/s40880-019-0380-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:56:52Z","timestamp":1773824212000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1186\/s40880-019-0380-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,27]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1186\/s40880-019-0380-x"],"URL":"https:\/\/doi.org\/10.1186\/s40880-019-0380-x","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,27]]},"assertion":[{"value":"2018-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"40"}}